Viridian Therapeutics price target raised to $45 from $41 at RBC Capital

RBC Capital raised the firm’s price target on Viridian Therapeutics (VRDN) to $45 from $41 and keeps an Outperform rating on the shares following the Q3 report. Despite the government shutdown, the company submitted the applicatoin for veligrotug in late October, the analyst tells investors in a research note. The firm thinks the drug offers “meaningful differentiation” from the standard-of-care Tepezza and is highly likely to gain approval.